Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Glue or coils? new study aims to settle best fix for pelvic pain

NCT ID NCT07221695

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to treat pelvic congestion syndrome, a condition that causes long-term pelvic pain. About 60 women aged 18–50 with moderate to severe pain will receive either foam plus medical glue or foam plus tiny coils to block the faulty vein. Researchers will track pain relief and symptom improvement over 18 months to see which method works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Female patients aged 18 to 50 years * Clinically suspected pelvic venous disorder (PVD), presenting with chronic pelvic pain ≥ 6 months * Pelvic pain intensity ≥ 4 on a 10-point Visual Analogue Scale (VAS) at baseline * No evidence of significant venous obstruction or internal iliac insufficiency * Willingness to participate, provide written informed consent, and comply with study visits and procedures exclusion criteria * Pregnancy or planning to conceive within the next 12 months * Significant Nutcracker syndrome diagnosed by duplex / CTV / MRV * Significant May-Thurner syndrome diagnosed by duplex / CTV / MRV * Non-ovarian sources of reflux requiring intervention, including internal iliac vein insufficiency; During venography all patients will undergo selective pelvic venography prior embolization to exclude patients who have combined gonadal and internal iliac vein reflux) * History of previous pelvic vein embolization or surgical ligation * Coagulopathy, defined as: * INR \> 1.5 * Platelet count \< 50 × 10⁹/L * Severe comorbidities, including: * Active pelvic infection (e.g., pelvic inflammatory disease) * End-stage renal disease (eGFR \< 30 mL/min/1.73 m²) * Decompensated heart failure (NYHA class III-IV) * Active malignancy requiring treatment Known allergy or hypersensitivity to: * Iodinated contrast media * Polidocanol (Aethoxysklerol®) * N-butyl cyanoacrylate (e.g., Gluebran® 2) * Nickel, platinum, or stainless steel (components of embolization coils) . Presence of non-venous pelvic pathology requiring immediate management

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pelvic congestive syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kafr El Shaykh University

    Kafr ash Shaykh, Kafrelshaykh Governorate, 33511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.